Heart Drug Growth Potential, Market Cap Drops by 700 Billion in a Day Due to Dilution Concerns

Cytokinetics Inc. (NASDAQ: CYTK) closed down 5.88% at $72.25 on June 1, wiping out roughly $500 million in market value. Trading volume exceeded 1.21 million shares, and the company’s market capitalization fell to about $8.99 billion.

The decline comes after Cytokinetics announced a $700 million common stock offering priced at $71 per share, raising concerns among investors about potential overhang in the near term.

In the first quarter, the company reported revenue of $19.4 million, significantly outperforming market expectations. With preparations underway for the global launch of its heart disease therapy aficamten and the recent approval of Mycorzo in Europe, long-term growth prospects remain intact.

Cytokinetics is a late-stage biotech specializing in cardiovascular treatments that target the myosin protein. Its pipeline includes aficamten for obstructive hypertrophic cardiomyopathy and omecamtiv mecarbil for heart failure. Aficamten, designated both an orphan drug and a breakthrough therapy in the U.S. and Europe, is widely seen as a key driver of future sales growth.